Clinical trial
A Phase 2, Double-Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects With External Genital Warts
NCT03981822 is registered in ClinicalTrials.gov with Verrica Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Double-Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects With External Genital Warts
- Lead sponsor
- Verrica Pharmaceuticals Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 25, 2019
- Completion date
- July 8, 2020
- Enrollment
- 105 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.